Teresa K Chen1, Christine Murakami1, Rebecca L Manno2, Duvuru Geetha3. 1. Division of Nephrology, Johns Hopkins Bayview Medical Center, The Johns Hopkins University School of Medicine, 301 Mason F. Lord Dr, Baltimore, MD 21224. 2. Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD. 3. Division of Nephrology, Johns Hopkins Bayview Medical Center, The Johns Hopkins University School of Medicine, 301 Mason F. Lord Dr, Baltimore, MD 21224. Electronic address: gduvura@jhmi.edu.
Abstract
OBJECTIVES: Hematuria is considered a marker of active renal disease in ANCA-associated glomerulonephritis (ANCA-GN) with induction immunosuppression often continued until hematuria has resolved. We aim to determine whether longer hematuria duration is associated with lower estimated glomerular filtration rate (eGFR) at 1 year. METHODS: We conducted a retrospective study of 55 patients with biopsy-proven ANCA-GN. Linear regression models were constructed to determine predictors of eGFR at 1 year. The primary exposure was hematuria (>5 rbc/hpf) duration, defined as <90 days vs. ≥ 90 days following renal biopsy. Covariates included age, gender, ANCA type, baseline eGFR, and baseline proteinuria. RESULTS: Mean age at diagnosis was 58 years (53% male, 80% Caucasian, 38% PR3-ANCA, and 45% MPO-ANCA). At baseline, all patients had hematuria, 95% had proteinuria, and mean serum creatinine was 3.1 [standard deviation (SD) = 2.3]mg/dL. Overall, 93% were treated with steroids in combination with either cyclophosphamide or rituximab. Mean hematuria duration was 92 (SD = 77) days with 34 (62%) patients having hematuria resolution within 90 days. Older age and lower baseline eGFR were associated with lower eGFR at 1 year (p = 0.03 and p < 0.001, respectively). Hematuria resolution (<90 days vs. ≥ 90 days) was not predictive of eGFR at 1 year (p = 0.93). CONCLUSIONS: In ANCA-GN, hematuria duration does not predict eGFR at 1 year. Our findings provide support that among individuals who are otherwise considered to be in clinical remission, the persistence of hematuria should not delay transition from induction to maintenance immunosuppression.
OBJECTIVES:Hematuria is considered a marker of active renal disease in ANCA-associated glomerulonephritis (ANCA-GN) with induction immunosuppression often continued until hematuria has resolved. We aim to determine whether longer hematuria duration is associated with lower estimated glomerular filtration rate (eGFR) at 1 year. METHODS: We conducted a retrospective study of 55 patients with biopsy-proven ANCA-GN. Linear regression models were constructed to determine predictors of eGFR at 1 year. The primary exposure was hematuria (>5 rbc/hpf) duration, defined as <90 days vs. ≥ 90 days following renal biopsy. Covariates included age, gender, ANCA type, baseline eGFR, and baseline proteinuria. RESULTS: Mean age at diagnosis was 58 years (53% male, 80% Caucasian, 38% PR3-ANCA, and 45% MPO-ANCA). At baseline, all patients had hematuria, 95% had proteinuria, and mean serum creatinine was 3.1 [standard deviation (SD) = 2.3]mg/dL. Overall, 93% were treated with steroids in combination with either cyclophosphamide or rituximab. Mean hematuria duration was 92 (SD = 77) days with 34 (62%) patients having hematuria resolution within 90 days. Older age and lower baseline eGFR were associated with lower eGFR at 1 year (p = 0.03 and p < 0.001, respectively). Hematuria resolution (<90 days vs. ≥ 90 days) was not predictive of eGFR at 1 year (p = 0.93). CONCLUSIONS: In ANCA-GN, hematuria duration does not predict eGFR at 1 year. Our findings provide support that among individuals who are otherwise considered to be in clinical remission, the persistence of hematuria should not delay transition from induction to maintenance immunosuppression.
Authors: J H Stone; G S Hoffman; P A Merkel; Y I Min; M L Uhlfelder; D B Hellmann; U Specks; N B Allen; J C Davis; R F Spiera; L H Calabrese; F M Wigley; N Maiden; R M Valente; J L Niles; K H Fye; J W McCune; E W St Clair; R A Luqmani Journal: Arthritis Rheum Date: 2001-04
Authors: Robert A F de Lind van Wijngaarden; Herbert A Hauer; Ron Wolterbeek; David R W Jayne; Gill Gaskin; Niels Rasmussen; Laure-Hélène Noël; Franco Ferrario; Rüdiger Waldherr; E Christiaan Hagen; Jan A Bruijn; Ingeborg M Bajema Journal: J Am Soc Nephrol Date: 2006-07-06 Impact factor: 10.121
Authors: J C Jennette; R J Falk; K Andrassy; P A Bacon; J Churg; W L Gross; E C Hagen; G S Hoffman; G G Hunder; C G Kallenberg Journal: Arthritis Rheum Date: 1994-02
Authors: David Jayne; Niels Rasmussen; Konrad Andrassy; Paul Bacon; Jan Willem Cohen Tervaert; Jolanta Dadoniené; Agneta Ekstrand; Gill Gaskin; Gina Gregorini; Kirsten de Groot; Wolfgang Gross; E Christiaan Hagen; Eduardo Mirapeix; Erna Pettersson; Carl Siegert; Alberto Sinico; Vladimir Tesar; Kerstin Westman; Charles Pusey Journal: N Engl J Med Date: 2003-07-03 Impact factor: 91.245
Authors: C Mukhtyar; O Flossmann; B Hellmich; P Bacon; M Cid; J W Cohen-Tervaert; W L Gross; L Guillevin; D Jayne; A Mahr; P A Merkel; H Raspe; D Scott; J Witter; H Yazici; R A Luqmani Journal: Ann Rheum Dis Date: 2007-10-02 Impact factor: 19.103
Authors: Claudia Yuste; Eduardo Gutierrez; Angel Manuel Sevillano; Alfonso Rubio-Navarro; Juan Manuel Amaro-Villalobos; Alberto Ortiz; Jesus Egido; Manuel Praga; Juan Antonio Moreno Journal: World J Nephrol Date: 2015-05-06
Authors: Rennie L Rhee; John C Davis; Linna Ding; Fernando C Fervenza; Gary S Hoffman; Cees G M Kallenberg; Carol A Langford; W Joseph McCune; Paul A Monach; Philip Seo; Robert Spiera; E William St Clair; Ulrich Specks; John H Stone; Peter A Merkel Journal: Clin J Am Soc Nephrol Date: 2018-01-25 Impact factor: 8.237
Authors: Claudia Yuste; Alfonso Rubio-Navarro; Daniel Barraca; Inés Aragoncillo; Almudena Vega; Soraya Abad; Alba Santos; Nicolás Macias; Ignacio Mahillo; Eduardo Gutiérrez; Manuel Praga; Jesús Egido; Juan Manuel López-Gómez; Juan Antonio Moreno Journal: PLoS One Date: 2015-05-27 Impact factor: 3.240